Modeling the health and economic burden of hepatitis C virus in Switzerland

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Müllhaupt, Beat ^a   Bruggmann, Philip ^b   Bihl, Florian ^c   Blach, Sarah ^d   Lavanchy, Daniel ^e   Razavi, Homie ^d   Semela, David ^f   Negro, Francesco ^g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Arud Centres for Addiction Medicine   (Switzerland)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d Center for Disease Analysis   (United States)

^e Consultant ^*  (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; COST OF ILLNESS; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; HEALTH CARE COST; HEALTH IMPACT ASSESSMENT; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICATION COMPLIANCE; MODEL; MORTALITY; OUTCOME ASSESSMENT; SWITZERLAND; ADOLESCENT; ADULT; ECONOMICS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; PATHOGENICITY;

HEPATITIS C VIRUS;

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SWITZERLAND;

EID: 84939142213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125214     Document Type: Article

References (37)

1. World Health Organization - Department of Immunization VaB (2006) State of the art of new vaccine research and development. Geneva, Switzerland. WHO/IVB/06. 01: 1-112.
2. Edlin BR (2011) Perspective: test and treat this silent killer. Nature 474: S18-S19. 474S18a [pii]; doi: 10.1038/474S18a PMID: 21697837
3. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107-115. doi: 10.1111/j.1469-0691.2010.03432.x PMID: 21091831
4. Wong JB, McQuillan GM, McHutchison JG, Poynard T (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90: 1562-1569. PMID: 11029989
5. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156: 271-278. 156/4/271 [pii]. doi: 10.1059/0003-4819-156-4-201202210-00004 PMID: 22351712
6. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS (2000) The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31: 777-782. S027091390085082X [pii]; doi: 10.1002/hep.510310332 PMID: 10706572
7. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313. S001650850234959X [pii]. PMID: 11984517
8. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. (2013) A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57: 230-236. cit234 [pii]; doi: 10.1093/cid/cit234 PMID: 23616492
9. Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, et al. (2013) Hepatitis B and C in Switzerland-healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med Wkly 143: 0. doi: 10.4414/smw.2013.13793; smw-13793 [pii].
10. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 31 Suppl 2: 30-60. doi: 10.1111/j.1478-3231.2011.02539.x PMID: 21651702
11. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 Suppl 1: 34-59. doi: 10.1111/jvh.12248 PMID: 24713005
12. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. (2014) Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21 Suppl 1: 5-33. doi: 10.1111/jvh.12247 PMID: 24713004
13. Sagmeister M, Renner EL, Mullhaupt B, Wong JB (2002) Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 14: 25-34. PMID: 11782572
14. Swiss Federal Office of Public Health (2013) Number of hepatitis C cases reported in Switzerland between 1988 and 2012 by year of birth (mandatory notification of laboratory confirmed cases): FOPH/ID/EPI/RIC.
15. The Swiss Hepatitis C Cohort Study (2014) Study Population; Some salient features. [cites April 15 2014] Available: http://www.swisshcv.ch/study-population.htm.
16. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714. 144/10/705 [pii]. PMID: 16702586
17. United Nations Department of Economic and Social Affairs Population Division (2011) World population prospects: The 2010 revision. Population database. [cited:Feb 1 2013]. Available: http://esa.un.org/unpd/wpp/index.htm.
18. Swiss Federal Office of Public Health (2013) Number of acute cases of hepatitis C in Switzerland by reporting year: FOPH/ID/EPI/RIC.
19. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333-1342. doi: 10.1002/hep.26141 PMID: 23172780
20. Swiss Federal Statistics Office (2011) Permanent foreign resident population by nationality by country and Canton, 1990-2010. su-f-1.3.1.1.23. Available: http://www.bfs.admin.ch/bfs.
21. University of California B, Max Planck Institute for Demographic Research (2013) Human Mortality Database. Jun 14 2013 [cited:Feb 1 2013]. Available: www.mortality.org.
22. Swiss Federal Statistics Office (2013) Fatalities by institutional divisions, gender, nationality, marital status and age group, 1971-2010. STAT-TAB: The interactive statistical database. [cited:Jun 17 2013] Available: http://www.pxweb.bfs.admin.ch/Dialog/statfile.asp?lang=1.
23. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M (2013) Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 91: 102-123. doi: 10.2471/BLT.12.108282; BLT.12.108282 [pii]. PMID: 23554523
24. Degenhardt L, Hall W, Warner-Smith M (2006) Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 82 Suppl 3: iii56-iii63. 82/suppl-3/iii56 [pii]; doi: 10.1136/sti.2005.019273 PMID: 16735295
25. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. (2009) Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf) 31: 374-382. fdp067 [pii]; doi: 10.1093/pubmed/fdp067 PMID: 19596666
26. Nordt C, Stohler R (2010) Combined effects of law enforcement and substitution treatment on heroin mortality. Drug Alcohol Rev 29: 540-545. DAR167 [pii]; doi: 10.1111/j.1465-3362.2009.00167.x PMID: 20887578
27. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F (2007) Cohort profile: The Swiss hepatitis C cohort study (SCCS). Int J Epidemiol 36: 731-737. dym096 [pii]; doi: 10.1093/ije/dym096 PMID: 17693458
28. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, et al. (2008) Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Euro Surveill 13.
29. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57: 2164-2170. doi: 10.1002/hep.26218 PMID: 23280550
30. IMS Health (2013) IMS Health MIDAS Data. IMS Health. Jan 1 2013 Available: http://www.imshealth.com/portal/site/ims/menuitem.edb2b81823f67dab41d84b903208c22a/?vgnextoid=4475e3de7e390310VgnVCM1000007f8c2ca2RCRD.
31. Evon DM, Verma A, Dougherty KA, Batey B, Russo M, Zacks S, et al. (2007) High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 52: 3251-3258. doi: 10.1007/s10620-006-9669-0 PMID: 17394072
32. Morrill JA, Shrestha M, Grant RW (2005) Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 20: 754-758. JGI05307 [pii]; doi: 10.1111/j.1525-1497.2005.0161.x PMID: 16050887
33. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. (2011) Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 364: 2199-2207. doi: 10.1056/NEJMoa1009370 PMID: 21631316
34. World Health Organization (2008) Task Shifting: Global Recommendations and Guidelines. 1-95.
35. Mdege ND, Chindove S, Ali S (2013) The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. Health Policy Plan 28: 223-236. czs058 [pii]; doi: 10.1093/heapol/czs058 PMID: 22738755
36. Aronsohn A, Jensen D (2014) Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology 59: 13-15. doi: 10.1002/hep.26590 PMID: 23788009
37. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61: 1-32. rr6104a1 [pii]. PMID: 23135062